Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsPaul Feuerstadt, MD, FACG, AGAF
Associate Clinical ProfessorAbout
Copy Link
Biography
A native of Long Island, New York, Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude.
Following completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, New York for his clinical fellowship training.
Throughout Dr. Feuerstadt’s training and practice he has been actively involved in research and other academic pursuits. His areas of interest include chronic diarrheal syndromes with a specific focus on Clostridiodes difficile infection, irritable bowel syndrome (IBS) and ischemic diseases of the gut. He has presented his research extensively at national meetings and has authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt’s is teaching, frequently giving lectures locally, regionally and nationally. Dr. Feuerstadt founded a website entitled "Everythingcdifficile.com" as an educational resource for patients and providers about this infectious disease. Finally, he is passionate about mentoring the fellows in the Division of Digestive Disease at Yale-New Haven Hospital where he holds a clinical appointment as an Assistant Clinical Professor of Medicine.
His clinical practice is his ultimate passion filling the majority of his work time as he sees a broad spectrum of patients with gastrointestinal and hepatic disease. Dr. Feuerstadt is affiliated with the St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital, and Milford Hospital.
Appointments
Digestive Diseases
Associate Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Montefiore Medical Center-Albert Einstein College of Medicine (2010)
- Categorical Resident
- New York Presbyterian Hospital-Weill Cornell Medical Center (2007)
- MD
- Weill Cornell Medical College (2004)
- BA
- University of Pennsylvania (2000)
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0002-7643-9576
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Kanika Sehgal, MBBS
Treatment Outcome
Publications
2026
When Does Clostridioides difficile “Recur”? Reconciling Epidemiologic and Bedside Recurrent C. difficile Infection Definitions
Khanna S, Feuerstadt P, Allegretti J, Pardi D. When Does Clostridioides difficile “Recur”? Reconciling Epidemiologic and Bedside Recurrent C. difficile Infection Definitions. Journal Of Infectious Diseases 2026, jiag307. PMID: 42304688, DOI: 10.1093/infdis/jiag307.Peer-Reviewed Original ResearchAltmetricConceptsRecurrent Clostridioides difficile infectionClostridioides difficile infectionTest of cureVariable follow-upClinical recurrenceEscalation therapyBowel dysfunctionFollow-upInfection definitionsTrial endpointsClinical syndromePositive testRecurrent illnessStrain typingRecurrenceCoded episodesTrialsRelapseTherapySyndromeDysfunctionClostridioidesReinfectionThe Changing Epidemiology of Clostridioides difficile Infection
Sehgal K, Feuerstadt P. The Changing Epidemiology of Clostridioides difficile Infection. Gastroenterology Clinics Of North America 2026 DOI: 10.1016/j.gtc.2026.05.001.Peer-Reviewed Original ResearchAGA Clinical Practice Update on Management of Clostridioides difficile Infection in Inflammatory Bowel Disease: Expert Review
Khanna S, Allegretti J, Hashash J, Feuerstadt P. AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Inflammatory Bowel Disease: Expert Review. Gastroenterology 2026, 171: 184-192. PMID: 42138670, DOI: 10.1053/j.gastro.2026.03.008.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsClostridioides difficile infectionRisk of Clostridioides difficile infectionInflammatory bowel diseaseClinical Practice Updates CommitteeRecurrent Clostridioides difficile infectionBest practice advice statementsPractice advice statementsSecondary preventionImmunosuppressive therapyEpisode of CDIHistory of Clostridioides difficile infectionRecurrence of Clostridioides difficile infectionConcurrent treatmentCDI riskBowel diseaseStandard procedures of GastroenterologyPrevention of Clostridioides difficile infectionAGA Governing BoardConcomitant cytomegalovirus infectionOral vancomycin prophylaxisClinical Practice UpdateTreatment of inflammatory bowel diseaseHigher surgical ratesHigher recurrence riskInflammatory bowel disease activitySa1741 EFFICACY AND SAFETY OF LINACLOTIDE IN IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C): A PHASE 3 POST HOC ANALYSIS BY RACE, ETHNICITY AND AGE
Staller K, Chang L, Ashok A, D’Achino D, Wu J, Tu P, Boules M, Feuerstadt P, Moshiree B. Sa1741 EFFICACY AND SAFETY OF LINACLOTIDE IN IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C): A PHASE 3 POST HOC ANALYSIS BY RACE, ETHNICITY AND AGE. Gastrointestinal Endoscopy 2026, 103: s-1842. DOI: 10.1016/s0016-5107(26)04373-7.Peer-Reviewed Original ResearchConceptsMo1420 ENGRAFTMENT AND MICROBIOME AND METABOLOME RESTORATION IN CDI-SCOPE, A PHASE 3B TRIAL OF FECAL MICROBIOTA, LIVE-JSLM ADMINISTERED BY COLONOSCOPY FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
Blount K, Khanna S, Feuerstadt P, Van Handel D, Ward T, Adamowicz B. Mo1420 ENGRAFTMENT AND MICROBIOME AND METABOLOME RESTORATION IN CDI-SCOPE, A PHASE 3B TRIAL OF FECAL MICROBIOTA, LIVE-JSLM ADMINISTERED BY COLONOSCOPY FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION. Gastrointestinal Endoscopy 2026, 103: s-353. DOI: 10.1016/s0016-5107(26)01088-6.Peer-Reviewed Original ResearchSa1741 EFFICACY AND SAFETY OF LINACLOTIDE IN IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C): A PHASE 3 POST HOC ANALYSIS BY RACE, ETHNICITY AND AGE
Staller K, Chang L, Ashok A, D’Achino D, Wu J, Tu P, Boules M, Feuerstadt P, Moshiree B. Sa1741 EFFICACY AND SAFETY OF LINACLOTIDE IN IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C): A PHASE 3 POST HOC ANALYSIS BY RACE, ETHNICITY AND AGE. Gastroenterology 2026, 170: s-1842. DOI: 10.1016/s0016-5085(26)04442-2.Peer-Reviewed Original ResearchConceptsMo1420 ENGRAFTMENT AND MICROBIOME AND METABOLOME RESTORATION IN CDI-SCOPE, A PHASE 3B TRIAL OF FECAL MICROBIOTA, LIVE-JSLM ADMINISTERED BY COLONOSCOPY FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
Blount K, Khanna S, Feuerstadt P, Van Handel D, Ward T, Adamowicz B. Mo1420 ENGRAFTMENT AND MICROBIOME AND METABOLOME RESTORATION IN CDI-SCOPE, A PHASE 3B TRIAL OF FECAL MICROBIOTA, LIVE-JSLM ADMINISTERED BY COLONOSCOPY FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION. Gastroenterology 2026, 170: s-353. DOI: 10.1016/s0016-5085(26)01157-1.Peer-Reviewed Original ResearchClostridioides difficile Infection: Harmonizing Patient Care
Allegretti J, Amin A, Hohmann E, Group A, Dubberke E, Feuerstadt P, Fischer M, Johnson S, Ziporyn T, Kelly C. Clostridioides difficile Infection: Harmonizing Patient Care. Gastro Hep Advances 2026, 5: 100896. PMID: 41852362, PMCID: PMC12993122, DOI: 10.1016/j.gastha.2026.100896.Peer-Reviewed Original ResearchAltmetricMulti-Species Synbiotic Supplementation After Antibiotics Promotes Recovery of Microbial Diversity and Function, and Increases Gut Barrier Integrity: A Randomized, Placebo-Controlled Trial
Napier B, Allegretti J, Feuerstadt P, Kelly C, Van Hise N, Jäger R, Stuivenberg G, Kassam Z, Reid G. Multi-Species Synbiotic Supplementation After Antibiotics Promotes Recovery of Microbial Diversity and Function, and Increases Gut Barrier Integrity: A Randomized, Placebo-Controlled Trial. Antibiotics 2026, 15: 138. PMID: 41750436, PMCID: PMC12937403, DOI: 10.3390/antibiotics15020138.Peer-Reviewed Original ResearchCitationsAltmetricConceptsGut barrier integrityBeneficial microbesMicrobiome compositionRecovery of microbial diversityFecal acetateButyrate-producing speciesPlacebo-controlled trialBarrier integrityGut microbiome diversityGut microbiome compositionMulti-speciesFecal microbiome compositionAlpha diversityGut barrier functionMicrobial diversityMicrobiome diversityButyrate levelsFecal butyrateGutProbiotic supplementationProof-of-mechanismMicrobiomeTreat infectionsUrolithin AMicrobesA Randomized, Placebo-Controlled Trial Evaluating Multi-Species Synbiotic Supplementation for Bloating, Gas, and Abdominal Discomfort
Allegretti J, Kassam Z, Kelly C, Grinspan A, El-Nachef N, Van Den Elzen C, Jäger R, Feuerstadt P. A Randomized, Placebo-Controlled Trial Evaluating Multi-Species Synbiotic Supplementation for Bloating, Gas, and Abdominal Discomfort. Nutrients 2026, 18: 255. PMID: 41599868, PMCID: PMC12845427, DOI: 10.3390/nu18020255.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAbdominal discomfortQuality-of-lifePlacebo-ControlledImpaired gut motilityGastrointestinal (GI) symptomsReal-world populationDouble-blindStatistically significant improvementVisceral hypersensitivityClinical outcomesBowel habitsGI symptomsPlaceboConstipation symptomsWeek 6Gut motilityHealthy individualsDaily supplementationMulti-speciesMood-related symptomsHealthy populationSymptomsSynbiotic supplementationConstipationDiscomfort
News
Copy Link
News
- March 03, 2026Source: GQ (with Dr. Paul Feuerstadt)
Should Poop Float or Sink?
- February 07, 2026Source: Parade Online (with Dr. Paul Feuerstadt)
I'm a Gastroenterologist-This Is the Worst Way To 'Fix' Bloating
- November 06, 2025Source: HCPLive
Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD
- February 18, 2025
Voluntary Faculty Awards Honor Outstanding Educators